Status:
COMPLETED
Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality
Lead Sponsor:
The Canadian College of Naturopathic Medicine
Collaborating Sponsors:
The Ottawa Hospital
Lotte & John Hecht Memorial Foundation
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
There is evidence to support the use of melatonin, a natural health product, as an additional treatment aid for cancer patients. This study is designed to see if the daily ingestion of 20 milligrams o...
Detailed Description
The trial employs a two-armed parallel placebo controlled trial design whereby patients with a diagnosis of non small cell lung cancer are randomized to receive either 20 mg of melatonin nightly or an...
Eligibility Criteria
Inclusion
- Clinical diagnosis of non small cell lung cancer
- Eligible for surgical resection
- Willingness to adhere to randomized treatment
- Availability for follow-up schedule of visits
Exclusion
- Taking exogenous melatonin
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2017
Estimated Enrollment :
709 Patients enrolled
Trial Details
Trial ID
NCT00668707
Start Date
September 1 2007
End Date
November 30 2017
Last Update
August 3 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Kelowna General Hospital
Kelowna, British Columbia, Canada, V1Y 4N7
2
Fraser Health
Surrey, British Columbia, Canada, V3R 7P8
3
QEII Health Sciences Centre/Capital Health
Halifax, Nova Scotia, Canada, B3H 2Y9
4
St. Joseph's/ McMaster University
Hamilton, Ontario, Canada, L8N 4A6